Last reviewed: May 20, 2026
Last updated: May 20, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Hair loss during GLP-1 therapy is not a direct pharmacological side effect of semaglutide or tirzepatide, but rather a consequence of rapid weight loss, caloric deficit, and potential micronutrient depletion. Clinical observation suggests hair shedding occurs in a subset of patients, typically 2–4 months after treatment initiation, coinciding with accelerated fat loss.
Understanding your individual nutritional status and genetic predispositions before starting GLP-1 therapy—whether branded or compounded—helps your provider design a preventive nutrition strategy. PlexusDx supports precision wellness by revealing genetic and biomarker context that informs personalized supplementation and monitoring protocols.
How Rapid Weight Loss Triggers Telogen Effluvium
Telogen effluvium is a reversible hair shedding condition triggered by metabolic stress, including sudden caloric deficit or rapid weight loss. During GLP-1 therapy, appetite suppression and increased satiety lead to significant daily caloric restriction—often 500–1,000 calories below baseline—which can push hair follicles prematurely into the telogen (resting) phase.
Hair follicles require stable energy and amino acid availability. When the body shifts into a sustained deficit, it reallocates resources away from non-essential functions like hair growth. Shedding typically manifests 6–12 weeks after the metabolic trigger begins, which aligns with the delayed timeline observed in GLP-1 users reporting hair concerns.
Micronutrient Deficiencies and Hair Follicle Health
Hair growth depends on adequate bioavailability of iron, zinc, vitamin B12, folate, protein, and selenium. GLP-1 medications slow gastric emptying and reduce overall food intake, limiting total nutrient absorption. Patients with pre-existing deficiencies—common in metabolic syndrome populations—face compounded risk during aggressive weight loss phases.
| Nutrient |
Role in Hair Health |
Risk During GLP-1 Use |
Monitoring Approach |
| Iron (ferritin) |
Oxygen transport to follicles; DNA synthesis in hair matrix cells |
Reduced intake + heavier menses in women = depletion risk |
Baseline ferritin; repeat at 3–6 months; consider supplementation if <30 ng/mL |
| Zinc |
Protein synthesis; immune regulation of follicle; androgen metabolism |
Reduced meat/seafood intake; GLP-1 may reduce absorption |
Serum zinc; avoid excessive supplementation (>40 mg/day) without monitoring |
| Vitamin B12 & folate |
DNA replication in rapidly dividing follicle cells; energy metabolism |
Reduced animal product intake; intrinsic factor changes with gastric pH reduction |
Baseline B12, homocysteine, folate; supplement if borderline or vegan/vegetarian |
| Protein & amino acids |
Structural component of hair shaft (keratin); fibroblast support |
Total caloric reduction = insufficient protein intake |
Target 1.0–1.2 g/kg body weight daily; monitor on scales + biomarkers |
Genetic Predisposition to Nutrient-Responsive Hair Loss
Genetic variants in nutrient sensing, iron metabolism, and androgen-related pathways may influence individual susceptibility to telogen effluvium during weight loss. Variants in TMPRSS6 (iron regulation), VDR (vitamin D sensing), and other loci affect baseline micronutrient status and follicle resilience under metabolic stress.
Patients with genetic predispositions to lower baseline iron saturation, vitamin D sensitivity, or altered zinc metabolism may experience hair shedding earlier or more severely during GLP-1 therapy. Identifying these patterns through genetic assessment allows providers to implement targeted supplementation and monitoring *before* initiating treatment.
Evaluating Hair Loss Risk and Prevention Strategies
Before starting GLP-1 therapy, a provider should assess baseline ferritin, iron saturation, B12, folate, vitamin D, zinc, and total protein status. Patients with low-normal or deficient levels warrant supplementation protocols designed to maintain follicle health during the weight loss phase. Gradual dose escalation of GLP-1 (rather than rapid titration) also allows the body to adapt metabolically.
Adequate protein intake—maintained at 1.0–1.2 g/kg ideal body weight—is non-negotiable during GLP-1 treatment. Prioritizing nutrient-dense, minimally processed foods (eggs, fish, legumes, leafy greens) ensures micronutrient bioavailability despite reduced total intake. Regular monitoring at 4–6 week intervals during initial weight loss helps catch deficiency markers before hair shedding becomes apparent.
How PlexusDx Supports a More Personalized Approach
PlexusDx's Precision Peptide Genetic Test may help provide context on your individual genetic predispositions in nutrient-sensing and metabolic stress-response pathways. While the test is not designed to predict exact GLP-1 response, it reveals genetic variants that inform baseline nutrient metabolism and follicle resilience—insights that should be interpreted with a qualified healthcare provider to shape supplementation strategy.
The Precision Peptide Genetic Test examines variants in nutrient-processing genes alongside GLP-1 receptor and metabolic pathways. Understanding your genetic predisposition to iron sensitivity, vitamin D sensing, and zinc utilization can guide your provider in selecting personalized micronutrient dosing *before* starting compounded semaglutide, tirzepatide, or other GLP-1 therapies. This is not a guarantee of outcome, but a data point for collaborative decision-making.
Adding genetic insight to your baseline biomarker profile (ferritin, B12, folate, zinc) creates a comprehensive picture for your provider. This informs whether you need intensive supplementation, closer monitoring intervals, or dose adjustment during your GLP-1 treatment journey. A provider trained in precision medicine can use both genetic and clinical data to minimize hair loss risk and support sustainable, healthy weight loss.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Ozempic for Weight Loss: Clinical Evidence & Genetic Factors
Semaglutide Cost Without Insurance: Biomarker-Informed Pricing